- In August 2024, Sound Pharmaceuticals aims to uphold its collaboration with WuXi AppTec for the production of its flagship Meniere’s disease medication, SPI-1005, despite the growing concerns regarding Chinese firms operating in the United States. The company recognizes the value of maintaining a reliable manufacturing partner to ensure the consistent supply of its drug. As the geopolitical landscape evolves, Sound Pharmaceuticals remains committed to navigating these challenges while continuing its vital partnership with WuXi AppTec
Frequently Asked Questions
The market is segmented based on Global Meniere’s Disease Treatment Market Segmentation, By Treatment (Drugs, Injections, and Surgery), End Users (Hospitals and Clinics, Specialty Centres, and Others) – Industry Trends and Forecast to 2031
.
The Global Menire Disease Treatment Market size was valued at USD 105.37 USD Billion in 2023.
The Global Menire Disease Treatment Market is projected to grow at a CAGR of 3.7% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
